Cargando…

A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

LESSONS LEARNED. Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions. BACKGROUND. Ofatumumab (OFA) is a fully humanized, anti‐CD20 antibody approved for use in chronic lymphocytic leukemia (CLL). The recommended administration re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2017
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634770/ https://www.ncbi.nlm.nih.gov/pubmed/28687625 http://dx.doi.org/10.1634/theoncologist.2017-0236

Ejemplares similares

Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
por: Flinn, Ian W., et al.
Publicado: (2019)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
por: Castillo, Jorge, et al.
Publicado: (2010)

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Phase II Study of S‐1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non‐Small Cell Lung Cancer
por: Chihara, Yusuke, et al.
Publicado: (2019)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2018)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas
por: Shepard, Gregg, et al.
Publicado: (2017)

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
por: Machiels, Jean-Pascal, et al.
Publicado: (2016)

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
por: Lieu, Christopher H., et al.
Publicado: (2017)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020)

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
por: Ko, Andrew H., et al.
Publicado: (2017)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
por: Nabhan, Chadi, et al.
Publicado: (2011)

A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
por: Uldrick, Thomas S., et al.
Publicado: (2017)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
por: El Dika, Imane, et al.
Publicado: (2018)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
por: AlDallal, Salma M
Publicado: (2017)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2016)

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study
por: Chen, San-Chi, et al.
Publicado: (2016)

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
por: Bendell, Johanna C., et al.
Publicado: (2016)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors
por: Olszanski, Anthony J., et al.
Publicado: (2016)

A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
por: Liu, Jian, et al.
Publicado: (2016)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
por: Chiappori, Alberto A., et al.
Publicado: (2016)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
por: Foss, Francine Marie, et al.
Publicado: (2018)

Chemoprevention in Patients with Peutz‐Jeghers Syndrome: Lessons Learned
por: de Brabander, Justin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cjdhi2sv7grqcm2bbgsjeghg0l